Draft:BabySeq

Research project, genomics From Wikipedia, the free encyclopedia

BabySeq is a research study evaluating the use of genome sequencing in newborns. It was launched in 2015 as the first randomized clinical trial to explore the medical, behavioral, and economic impacts of incorporating genomic sequencing into routine newborn care.[1]

Background

The project was initiated by investigators at Mass General Brigham, Harvard Medical School, and Boston Children's Hospital, with support from the National Institutes of Health (NIH). Its goal is to understand how comprehensive genomic data can be integrated into newborn and pediatric care, and how families and clinicians interpret and act on such findings.[1][2]

BabySeq2

A second phase of the project, sometimes referred to as BabySeq2, is an implementation study designed to expand on findings from the original trial. The study has enrolled over 700 newborns across sites in Birmingham, Alabama; Boston, Massachusetts; Detroit, Michigan; Lebanon, New Hampshire; Madison, Wisconsin; Miami, Florida; Minneapolis, Minnesota; New York City, New York; Philadelphia, Pennsylvania; and Stanford, California, with an emphasis on recruiting a diverse cohort of families.[2] The project aims to evaluate how genomic information is communicated and used in clinical settings and how genomic information can impact healthcare throughout childhood.[3]

Findings

BabySeq has contributed data on the frequency and impact of monogenic disease variants identified through genome sequencing among otherwise healthy newborns,[4] as well as ethical and psychosocial outcomes for families.[5] A 2025 New York Times article mentioned BabySeq among studies exploring the expanding role of genomic testing in infants.[6]



References

Related Articles

Wikiwand AI